Skip Nav Destination
Issues
15 August 2020
-
Cover Image
Cover Image
The cover shows multiplex immunofluorescence staining of a human NSCLC case (cytokeratin in green, CD3 in red, and CD56 in white). There is abundant CD56 expression in the stroma, including CD56+/CD3− cells (NK cells) and CD56+/CD3+ cells (NKT cells). For details, see the article by Zugazagoitia and colleagues on page 4360 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer
Suparna Wedam; Lola Fashoyin-Aje; Xin Gao; Erik Bloomquist; Shenghui Tang; Rajeshwari Sridhara; Kirsten B. Goldberg; Bellinda L. King-Kallimanis; Marc R. Theoret; Amna Ibrahim; Laleh Amiri-Kordestani; Richard Pazdur; Julia A. Beaver
Review
Perspectives
Clinical Trials: Targeted Therapy
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
Stephanie Lheureux; Ana Oaknin; Swati Garg; Jeffrey P. Bruce; Ainhoa Madariaga; Neesha C. Dhani; Valerie Bowering; Justin White; Sarah Accardi; Qian Tan; Marsela Braunstein; Katherine Karakasis; Iulia Cirlan; Stephanie Pedersen; Tiantiam Li; Lorena Fariñas-Madrid; Yeh Chen Lee; Zhihui (Amy) Liu; Trevor J. Pugh; Amit M. Oza
Author Choice
Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
Yuqin Song; Keshu Zhou; Dehui Zou; Jianfeng Zhou; Jianda Hu; Haiyan Yang; Huilai Zhang; Jie Ji; Wei Xu; Jie Jin; Fangfang Lv; Ru Feng; Sujun Gao; Haiyi Guo; Lei Zhou; Rebecca Elstrom; Jane Huang; William Novotny; Rachel Wei; Jun Zhu
A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma
Sant P. Chawla; Sanjay Goel; Warren Chow; Fadi Braiteh; Arun S. Singh; Juneko E. Grilley Olson; Atsushi Osada; Iulian Bobe; Richard F. Riedel
Author Choice
NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response
Sandra M. Swain; Gong Tang; Heather Ann Brauer; David S. Goerlitz; Peter C. Lucas; André Robidoux; Brent T. Harris; Hanna Bandos; Yuqi Ren; Charles E. Geyer, Jr; Priya Rastogi; Eleftherios P. Mamounas; Norman Wolmark
Author Choice
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2− Primary Breast Cancer
John F.R. Robertson; Abigail Evans; Stephan Henschen; Cliona C. Kirwan; Ali Jahan; Laura M. Kenny; J. Michael Dixon; Peter Schmid; Ashutosh Kothari; Omar Mohamed; Peter A. Fasching; Kwok-Leung Cheung; Rachel Wuerstlein; Danielle Carroll; Teresa Klinowska; Justin P.O. Lindemann; Alexander MacDonald; Richard Mather; Rhiannon Maudsley; Michele Moschetta; Myria Nikolaou; Martine P. Roudier; Tinnu Sarvotham; Gaia Schiavon; Diansong Zhou; Li Zhou; Nadia Harbeck
Clinical Trials: Immunotherapy
Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial
Bixia Tang; Zhihong Chi; Yingbo Chen; Xiufeng Liu; Di Wu; Jing Chen; Xin Song; Weifeng Wang; Lihou Dong; Haifeng Song; Hai Wu; Hui Feng; Sheng Yao; Shuikui Qin; Xiaoshi Zhang; Jun Guo
Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Jared Weiss; Siddharth Sheth; Allison M. Deal; Juneko E. Grilley Olson; Samip Patel; Trevor G. Hackman; Jeffrey M. Blumberg; Thomas J. Galloway; Shetal Patel; Adam M. Zanation; Colette J. Shen; D. Neil Hayes; Christopher Hilliard; Ranee Mehra; Karen P. McKinnon; Hsing-Hui Wang; Mark Christian Weissler; Jessica R. Bauman; Bhishamjit S. Chera; Benjamin G. Vincent
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
Erika J. Lampert; Alexandra Zimmer; Michelle Padget; Ashley Cimino-Mathews; Jayakumar R. Nair; Yingmiao Liu; Elizabeth M. Swisher; James W. Hodge; Andrew B. Nixon; Erin Nichols; Mohammad H. Bagheri; Elliott Levy; Marc R. Radke; Stanley Lipkowitz; Christina M. Annunziata; Janis M. Taube; Seth M. Steinberg; Jung-Min Lee
Precision Medicine and Imaging
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis
Kelly J. Norsworthy; Flora Mulkey; Emma C. Scott; Ashley F. Ward; Donna Przepiorka; Rosane Charlab; Sarah E. Dorff; Albert Deisseroth; Dickran Kazandjian; Rajeshwari Sridhara; Julia A. Beaver; Ann T. Farrell; R. Angelo de Claro; Richard Pazdur
The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones
Isabel C. Poschke; Jessica C. Hassel; Aaron Rodriguez-Ehrenfried; Katharina A.M. Lindner; Ignacio Heras-Murillo; Lena M. Appel; Johanna Lehmann; Tanja Lövgren; Stina L. Wickström; Claudia Lauenstein; Jasmin Roth; Anna-Katharina König; John B.A.G. Haanen; Joost van den Berg; Rolf Kiessling; Frank Bergmann; Michael Flossdorf; Oliver Strobel; Rienk Offringa
The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer
Sarah McCuaig; David Barras; Elizabeth H. Mann; Matthias Friedrich; Samuel J. Bullers; Alina Janney; Lucy C. Garner; Enric Domingo; Viktor Hendrik Koelzer; Mauro Delorenzi; Sabine Tejpar; Timothy S. Maughan; Nathaniel R. West; Fiona Powrie
Prognostic Significance of Immune Cell Populations Identified by Machine Learning in Colorectal Cancer Using Routine Hematoxylin and Eosin–Stained Sections
Juha P. Väyrynen; Mai Chan Lau; Koichiro Haruki; Sara A. Väyrynen; Andressa Dias Costa; Jennifer Borowsky; Melissa Zhao; Kenji Fujiyoshi; Kota Arima; Tyler S. Twombly; Junko Kishikawa; Simeng Gu; Saina Aminmozaffari; Shanshan Shi; Yoshifumi Baba; Naohiko Akimoto; Tomotaka Ugai; Annacarolina Da Silva; Mingyang Song; Kana Wu; Andrew T. Chan; Reiko Nishihara; Charles S. Fuchs; Jeffrey A. Meyerhardt; Marios Giannakis; Shuji Ogino; Jonathan A. Nowak
Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non–Small Cell Lung Cancer
Bin Liu; Julio Ricarte Filho; Apurva Mallisetty; Cassandra Villani; Anastasia Kottorou; Kristen Rodgers; Chen Chen; Tomoaki Ito; Kyla Holmes; Nicole Gastala; Klara Valyi-Nagy; Odile David; Ron C. Gaba; Christian Ascoli; Mary Pasquinelli; Lawrence E. Feldman; Malek G. Massad; Tza-Huei Wang; Ignacio Jusue-Torres; Enrico Benedetti; Robert A. Winn; Malcolm V. Brock; James G. Herman; Alicia Hulbert
Translational Cancer Mechanisms and Therapy
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer
Nellie K. McDaniel; Mari Iida; Kwangok P. Nickel; Colin A. Longhurst; Samantha R. Fischbach; Tamara S. Rodems; Carlene A. Kranjac; Amber Y. Bo; Qianyun Luo; Meghan M. Gallagher; Noah B. Welke; Kaitlyn R. Mitchell; Alison E. Schulz; Jaimee C. Eckers; Rong Hu; Ravi Salgia; Seungpyo Hong; Justine Y. Bruce; Randall J. Kimple; Deric L. Wheeler
Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules
Maxime Meylan; Florent Petitprez; Laetitia Lacroix; Luca Di Tommaso; Massimo Roncalli; Antoine Bougoüin; Alexis Laurent; Giuliana Amaddeo; Daniele Sommacale; Hélène Regnault; Jonathan Derman; Cécile Charpy; Fouad Lafdil; Jean-Michel Pawlotsky; Catherine Sautès-Fridman; Wolf H. Fridman; Julien Calderaro
CD8+ T-cell–Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas
Joshua R. Kane; Junfei Zhao; Takashi Tsujiuchi; Brice Laffleur; Víctor A. Arrieta; Aayushi Mahajan; Ganesh Rao; Angeliki Mela; Crismita Dmello; Li Chen; Daniel Y. Zhang; Edgar González-Buendia; Catalina Lee-Chang; Ting Xiao; Gerson Rothschild; Uttiya Basu; Craig Horbinski; Maciej S. Lesniak; Amy B. Heimberger; Raul Rabadan; Peter Canoll; Adam M. Sonabend
Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
Jennifer X. Ji; Dawn R. Cochrane; Basile Tessier-Cloutier; Shary Yutin Chen; Germain Ho; Khyatiben V. Pathak; Isabel N. Alcazar; David Farnell; Samuel Leung; Angela Cheng; Christine Chow; Shane Colborne; Gian Luca Negri; Friedrich Kommoss; Anthony Karnezis; Gregg B. Morin; Jessica N. McAlpine; C. Blake Gilks; Bernard E. Weissman; Jeffrey M. Trent; Lynn Hoang; Patrick Pirrotte; Yemin Wang; David G. Huntsman
Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition
Lucas Basler; Hubert S. Gabryś; Sabrina A. Hogan; Matea Pavic; Marta Bogowicz; Diem Vuong; Stephanie Tanadini-Lang; Robert Förster; Ken Kudura; Martin W. Huellner; Reinhard Dummer; Matthias Guckenberger; Mitchell P. Levesque
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds